Literature DB >> 32632271

Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy.

Mathilde Feist1,2, Zhi Zhu1, Enyong Dai1,3, Congrong Ma1, Zuqiang Liu1,2, Esther Giehl1,2, Roshni Ravindranathan1, Stacy J Kowalsky1, Natasa Obermajer1, Udai S Kammula1, Andrew J H Lee1, Michael T Lotze1, Zong Sheng Guo4, David L Bartlett5,6.   

Abstract

Adoptive cell therapy (ACT) using tumor-specific tumor-infiltrating lymphocytes (TILs) has demonstrated success in patients where tumor-antigen specific TILs can be harvested from the tumor, expanded, and re-infused in combination with a preparatory regimen and IL2. One major issue for non-immunogenic tumors has been that the isolated TILs lack tumor specificity and thus possess limited in vivo therapeutic function. An oncolytic virus (OV) mediates an immunogenic cell death for cancer cells, leading to elicitation and dramatic enhancement of tumor-specific TILs. We hypothesized that the tumor-specific TILs elicited and promoted by an OV would be a great source for ACT for solid cancer. In this study, we show that a local injection of oncolytic poxvirus in MC38 tumor with low immunogenicity in C57BL/6 mice, led to elicitation and accumulation of tumor-specific TILs in the tumor tissue. Our analyses indicated that IL2-armed OV-elicited TILs contain lower quantities of exhausted PD-1hiTim-3+ CD8+ T cells and regulatory T cells. The isolated TILs from IL2-expressing OV-treated tumor tissue retained high tumor specificity after expansion ex vivo. These TILs resulted in significant tumor regression and improved survival after adoptive transfer in mice with established MC38 tumor. Our study showcases the feasibility of using an OV to induce tumor-reactive TILs that can be expanded for ACT.

Entities:  

Mesh:

Year:  2020        PMID: 32632271     DOI: 10.1038/s41417-020-0189-4

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  59 in total

1.  Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.

Authors:  Steven A Rosenberg; James C Yang; Richard M Sherry; Udai S Kammula; Marybeth S Hughes; Giao Q Phan; Deborah E Citrin; Nicholas P Restifo; Paul F Robbins; John R Wunderlich; Kathleen E Morton; Carolyn M Laurencot; Seth M Steinberg; Donald E White; Mark E Dudley
Journal:  Clin Cancer Res       Date:  2011-04-15       Impact factor: 12.531

Review 2.  Adoptive cell transfer as personalized immunotherapy for human cancer.

Authors:  Steven A Rosenberg; Nicholas P Restifo
Journal:  Science       Date:  2015-04-03       Impact factor: 47.728

Review 3.  The immune contexture in cancer prognosis and treatment.

Authors:  Wolf H Fridman; Laurence Zitvogel; Catherine Sautès-Fridman; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2017-07-25       Impact factor: 66.675

4.  Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study.

Authors:  Smita S Chandran; Robert P T Somerville; James C Yang; Richard M Sherry; Christopher A Klebanoff; Stephanie L Goff; John R Wunderlich; David N Danforth; Daniel Zlott; Biman C Paria; Arvind C Sabesan; Abhishek K Srivastava; Liqiang Xi; Trinh H Pham; Mark Raffeld; Donald E White; Mary Ann Toomey; Steven A Rosenberg; Udai S Kammula
Journal:  Lancet Oncol       Date:  2017-04-07       Impact factor: 41.316

Review 5.  Cancer immunotherapy: harnessing the immune system to battle cancer.

Authors:  Yiping Yang
Journal:  J Clin Invest       Date:  2015-09-01       Impact factor: 14.808

6.  Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.

Authors:  Antoni Ribas; Reinhard Dummer; Igor Puzanov; Ari VanderWalde; Robert H I Andtbacka; Olivier Michielin; Anthony J Olszanski; Josep Malvehy; Jonathan Cebon; Eugenio Fernandez; John M Kirkwood; Thomas F Gajewski; Lisa Chen; Kevin S Gorski; Abraham A Anderson; Scott J Diede; Michael E Lassman; Jennifer Gansert; F Stephen Hodi; Georgina V Long
Journal:  Cell       Date:  2017-09-07       Impact factor: 41.582

7.  Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.

Authors:  Rikke Andersen; Marco Donia; Eva Ellebaek; Troels Holz Borch; Per Kongsted; Trine Zeeberg Iversen; Lisbet Rosenkrantz Hölmich; Helle Westergren Hendel; Özcan Met; Mads Hald Andersen; Per Thor Straten; Inge Marie Svane
Journal:  Clin Cancer Res       Date:  2016-03-22       Impact factor: 12.531

8.  Efficient and reproducible generation of tumour-infiltrating lymphocytes for renal cell carcinoma.

Authors:  V Baldan; R Griffiths; R E Hawkins; D E Gilham
Journal:  Br J Cancer       Date:  2015-03-17       Impact factor: 7.640

9.  Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy.

Authors:  Zuqiang Liu; Roshni Ravindranathan; Pawel Kalinski; Z Sheng Guo; David L Bartlett
Journal:  Nat Commun       Date:  2017-03-27       Impact factor: 14.919

10.  Heating it up: Oncolytic viruses make tumors 'hot' and suitable for checkpoint blockade immunotherapies.

Authors:  Shashi Gujar; Jonathan G Pol; Guido Kroemer
Journal:  Oncoimmunology       Date:  2018-03-13       Impact factor: 8.110

View more
  11 in total

1.  Ferroptosis Inducer Improves the Efficacy of Oncolytic Virus-Mediated Cancer Immunotherapy.

Authors:  Weilin Liu; Hongqi Chen; Zhi Zhu; Zuqiang Liu; Congrong Ma; Yong J Lee; David L Bartlett; Zong-Sheng Guo
Journal:  Biomedicines       Date:  2022-06-15

Review 2.  Controlling Cell Trafficking: Addressing Failures in CAR T and NK Cell Therapy of Solid Tumours.

Authors:  Lydia G White; Hannah E Goy; Alinor J Rose; Alexander D McLellan
Journal:  Cancers (Basel)       Date:  2022-02-15       Impact factor: 6.639

3.  In Vivo Priming of Peritoneal Tumor-Reactive Lymphocytes With a Potent Oncolytic Virus for Adoptive Cell Therapy.

Authors:  Esther Giehl; Hiromichi Kosaka; Zuqiang Liu; Mathilde Feist; Udai S Kammula; Michael T Lotze; Congrong Ma; Zong Sheng Guo; David L Bartlett
Journal:  Front Immunol       Date:  2021-02-18       Impact factor: 7.561

4.  Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma.

Authors:  Alvaro Morales-Molina; Stefano Gambera; Angela Leo; Javier García-Castro
Journal:  J Immunother Cancer       Date:  2021-03       Impact factor: 13.751

Review 5.  Oncolytic Viruses and Cancer, Do You Know the Main Mechanism?

Authors:  Wesam Kooti; Hadi Esmaeili Gouvarchin Ghaleh; Mahdieh Farzanehpour; Ruhollah Dorostkar; Bahman Jalali Kondori; Masoumeh Bolandian
Journal:  Front Oncol       Date:  2021-12-22       Impact factor: 6.244

6.  Oncolytic adenovirus-mediated expression of decorin facilitates CAIX-targeting CAR-T therapy against renal cell carcinoma.

Authors:  Chen Zhang; Lin Fang; Xueyan Wang; Sen Yuan; Wanjing Li; Weiping Tian; Jing Chen; Qi Zhang; Yuxin Zhang; Qing Zhang; Junnian Zheng
Journal:  Mol Ther Oncolytics       Date:  2021-11-29       Impact factor: 7.200

Review 7.  Engineering strategies to enhance oncolytic viruses in cancer immunotherapy.

Authors:  Yaomei Tian; Daoyuan Xie; Li Yang
Journal:  Signal Transduct Target Ther       Date:  2022-04-06

8.  Oncolytic adenovirus decreases the proportion of TIM-3+ subset of tumor-infiltrating CD8+ T cells with correlation to improved survival in patients with cancer.

Authors:  Ilkka Liikanen; Saru Basnet; Dafne C A Quixabeira; Kristian Taipale; Otto Hemminki; Minna Oksanen; Matti Kankainen; Juuso Juhila; Anna Kanerva; Timo Joensuu; Siri Tähtinen; Akseli Hemminki
Journal:  J Immunother Cancer       Date:  2022-02       Impact factor: 13.751

Review 9.  Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges.

Authors:  Yueshui Zhao; Jian Deng; Shuangfeng Rao; Sipeng Guo; Jing Shen; Fukuan Du; Xu Wu; Yu Chen; Mingxing Li; Meijuan Chen; Xiaobing Li; Wanping Li; Li Gu; Yuhong Sun; Zhuo Zhang; Qinglian Wen; Zhangang Xiao; Jing Li
Journal:  Cancers (Basel)       Date:  2022-08-27       Impact factor: 6.575

Review 10.  Strategies to Develop Potent Oncolytic Viruses and Enhance Their Therapeutic Efficacy.

Authors:  Omeed Moaven; Christopher W Mangieri; John A Stauffer; Panos Z Anastasiadis; Mitesh J Borad
Journal:  JCO Precis Oncol       Date:  2021-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.